Evaluation of antioxiodant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model

Journal of Cellular Physiology

Volumn 225, Issue 1, 2010, Pages 84-91

  Tinti, Laura ^a   Spreafico, Adriano ^a   Braconi, Daniela ^a   Millucci, Lia ^a   Bernardini, Giulia ^a   Chellini, Federico ^a   Cavallo, Giovanni ^a   Selvi, Enrico ^a   Galeazzi, Mauro ^a   Marcolongo, Roberto ^a   Gallagher, James A ^a,b   Santucci, Annalisa ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ASCORBIC ACID; HOMOGENTISIC ACID; PROTEOGLYCAN; ANTIOXIDANT; HOMOGENTISATE 1,2 DIOXYGENASE;

ALKAPTONURIA; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CARTILAGE CELL; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; CLINICAL EVALUATION; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN CARBONYLATION; TREATMENT OUTCOME; ARTICULAR CARTILAGE; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; EVALUATION; GENETICS; METABOLISM; OCHRONOSIS; PATHOLOGY;

ACETYLCYSTEINE; ALKAPTONURIA; ANTIOXIDANTS; APOPTOSIS; ASCORBIC ACID; CARTILAGE, ARTICULAR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CHONDROCYTES; HOMOGENTISATE 1,2-DIOXYGENASE; HOMOGENTISIC ACID; HUMANS; OCHRONOSIS; PROTEIN CARBONYLATION;

EID: 77956553614     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22199     Document Type: Article

References (40)

1. Angeles AP, Badger R, Gruber HE, Seegmiller JE. 1989. Chondrocyte growth inhibition induced by homogentisic acid and its partial prevention with ascorbic acid. J Rheumatol 16:4-7.
2. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
3. Candiano G, Bruschi M, Musante L, Santucci L, Ghiggeri GM, Carnemolla B, Orecchia P, Zardi L, Righetti PG. 2004. Blue silver: A very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 25:1327-1333. (Pubitemid 38801651)
4. Chindamo D, Catenaccio M, Lorenzini S, Selvi E, Molinelli M, Cavallo G, Marcolongo R. 2003. N-acetylcysteine and vitamin E: An in vitro study of their effect on homogentisic acid polymerization. Clin Exp Rheumatol 21:269.
5. D'Agostini F, Balansky RM, Camoirano A, de Flora S. 2000. Interactions between N-acetylcysteine and ascorbic acid in modulating mutagenesis and carcinogenesis. Int J Cancer 88:702-707.
6. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. 2003. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 329:23-38.
7. De Flora S, Cesarone CF, Balansky RM, Albini A, D'Agostini F, Bennicelli C, Bagnasco M, Camoirano A, Scatolini L, Rovida A, Izzotti A. 1995. Chemopreventive properties and mechanisms of N-Acetylcysteine. The experimental background. J Cell Biochem Suppl 22:33-41.
8. de Haas V, Carbasius Weber EC, de Klerk JB, Bakker HD, Smit GP, Huijbers WA, Duran M, Poll-The BT. 1998. The success of dietary protein restriction in alkaptonuria patients is age-dependent. J Inherit Metab Dis 21:791-798. (Pubitemid 28558675)
9. Denizot F, Lang R. 1986. Rapid colorimetric assay for cell growth and survival. Modification to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 22:271-277.
10. Fernández-Cañón JM, Granadino B, Beltrán- Valero de Bernabé D, Renedo M, Fernández-Ruiz E, Peñalva MA, Rodríguez de Córdoba S. 1996. The molecular basis of alkaptonuria. Nat Genet 14:19-24.
11. Forslind K, Wollheim FA, Akesson B, Rydholm U. 1988. Alkaptonuria and ochronosis in three siblings. Ascorbic acid treatment monitored by urinary HGA excretion. Clin Exp Rheumatol 6:289-292.
12. Gaines JJ. 1989. The pathology of alkaptonuric ochronosis. Hum Pathol 20:40-46.
13. Grigolo B, Roseti L, Neri S, Gobbi P, Jensen P, Major EO, Facchini A. 2002. Human articular chondrocytes immortalized by HPV-16 E6 and E7 genes: Maintenance of differentiated phenotype under defined culture conditions. Osteoarthritis Cartilage 10:879-889.
14. Helliwell TR, Gallagher JA, Ranganath L. 2008. Alkaptonuria - A review of surgical and autopsy pathology. Histopathology 53:503-512.
15. Introne WJ, Phornphutkul C, Bernardini I, McLaughlin K, Fitzpatrick D, Gahl WA. 2002. Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation. Mol Genet Metab 77:136-142.
16. Kayser MA, Introne WJ, Gahl WA. 2008. Alkaptonuria. In: Valle D, et al. editors. New online metabolic and molecular basis of inherited disease. New York: McGraw Hill. http://www.ommbid.com.
17. Keller JM, Macaulay W, Nercessian OA, Jaffe IA. 2005. New developments in ochronosis: Review of the literature. Rheumatol Int 25:81-85. (Pubitemid 40468925)
18. Kirkpatrick CJ, Mohr W, Mutschler W. 1984. Experimental studies on the pathogenesis of ochronotic arthropathy. Virchows Arch [Cell Pathol] 47:347-360.
19. Kobak AC, Oder G, Kobak S, Argin M, Inal V. 2005. Ochronotic arthropathy: Disappearance of alkaptonuria after liver transplantation for hepatitis B-related cirrhosis. J Clin Rheumatol 11:323-325.
20. Kutty MK, Iqbal QM, Teh EC. 1974. Ochronotic arthropathy. An electron microscopic study with a view on pathogenesis. Arch Pathol Lab Med 98:55-57.
21. La Du BN. 2001. Alkaptonuria. In: Scriver CR, Beaud AL, Sly WS, Valle D, editors. The metabolic & molecular bases of inherited disease, Vol. 2, 8th edition. New York: McGraw-Hill. pp 2109-2123.
22. La Du BN. 2002. Alkaptonuria. In: Royce PM, Steinmann B, editors. Connective tissue and its heritable disorders, 2nd edition. New York: John Wiley. pp 809-826.
23. La Du BN, Zannoni VG, Laster L, Seegmiller JE. 1958. The nature of the defect in tyrosine metabolism in alkaptonuria. J Biol Chem 230:251-260.
24. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
25. Lorenzini S, Mannoni A, Selvi E. 2003. Alkaptonuria. N Engl J Med 348:1408.
26. Manning K, Fernández-Cañón JM, Montagutelli X, Grompe M. 1999. Identification of the mutation in the alkaptonuria mouse model, mutations in brief no. 216. Online. Hum Mutat 13:171.
27. Mannoni A, Selvi E, Lorenzini S, Giorgi M, Airó P, Cammelli D, Andreotti L, Marcolongo R, Porfirio B. 2004. Alkaptonuria, ochronosis and ochronotic arthropathy. Semin Arthritis Rheum 33:239-248.
28. Martin JP, Batkoff B. 1987. Homogentisic acid autoxidation and oxygen radical generation: Implications for the etiology of alkaptonuric arthritis. Free Rad Biol Med 3:241-250.
29. Meister A. 1992. On the antioxidant effects of ascorbic acid and glutathione. Biochem Pharmacol 44:1905-1915.
30. Montagutelli X, Lalouette A, Coudé M, Kamoun P, Forest M, Guénet JL. 1994. Aku, a mutation of the mouse homologous to human alkaptonuria, maps to chromosome 16. Genomics 19:9-11. (Pubitemid 24034358)
31. Morita K, Miyamoto T, Fujita N, Kubota Y, Ito K, Takubo K, Miyamoto K, Ninomiya K, Suzuki T, Iwasaki R, Yagi M, Takaishi H, Toyama Y, Suda T. 2007. Reactive oxygen species induce chondrocyte hypertrophy in endochondral ossification. J Exp Med 204:1613-1623.
32. O'Brien WM, La Du BN, Bunim JJ. 1963. Biochemical, pathologic and clinical aspects of alkaptonuria, ochronosis and ochronotic arthropathy: Review of world literature (1584-1962). Am J Med 34:813-838.
33. Phornphutkul C, Introne WJ, Perry MB, Bernardini I, Murphey MD, Fitzpatrick DL, Anderson PD, Huizing M, Anikster Y, Gerber LH, Gahl WA. 2002. Natural history of alkaptonuria. New Engl J Med 347:2111-2121.
34. Selvi E, Manganelli S, Mannoni A, Benucci M, Minacci C, Marcolongo R. 2000. Chronic ochronotic arthritis: Clinical, arthroscopic and pathologic findings. J Rheumatol 27:27-29.
35. Suwannarat P, O'Brien K, Perry MB, Sebring N, Bernardini I, Kaiser-Kupfer MI, Rubin BI, Tsilou E, Gerber LH, Gahl WA. 2005. Use of nitisinone in patientswith alkaptonuria. Metab Clin Exp 54:719-717.
36. Suzuki Y, Oda K, Yoshikawa Y, Maeda Y, Suzuki T. 1999. A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria. J Hum Genet 44:79-84.
37. Taylor AM, Wlodarski B, Prior IA, Wilson PJM, Jarvis JC, Ranganth LR, Gallagher JA. 2010. Ultrastructural examination of tissue in a patient with alkaptonuric arthropathy reveals a distinct pattern of binding of ochronotic pigment. Rheumatology. Epub ahead of print.
38. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. 1995. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V. J Immunol Methods 184:39-51.
39. Wolff JA, Barshop B, Nyhan WL, Leslie J, Seegmiller JE, Gruber H, Garst M, Winter S, Michals K, Matalon R. 1989. Effects of ascorbic acid in alkapronuria: Alterations in benzoquinone acetic acid and an ontogenic effect in infancy. Pediatr Res 26:140-144.
40. Zannoni VG, Malwista SE, La Du BN. 1962. Studies on ochronosis II. Studies on benzoquinoneacetic acid, a probable intermediate in the connective tissue pigmentation in alkaptonuria. Arthritis Rheum 5:547-556.